Veloxis Pharmaceuticals A/S and Athena Drug Delivery Solutions Pvt. Ltd. Announce Partnership to Develop, Manufacture and Commercialize Its Investigational Drug Atorfen™ (Fenofibrate-Atorvastin Fixed Dose Combination) in Certain Emerging Markets

HORSHOLM, Denmark, Dec. 23, 2011 — (PRNewswire) —  Veloxis Pharmaceuticals A/S (OMX: VELO) and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen™  (Fenofibrate Atorvastatin fixed dose combination).

AtorFen™ will contain the lowest fully effective dose of fenofibrate and is a combination of two effective dyslipidemia treatments in one tablet thereby potentially improving patient compliance.  The product has been developed by Veloxis through Phase II in the US. Results showed significant improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with atorvastatin alone (Lipitor® 40 mg) as well as significantly greater effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with fenofibrate alone (Tricor® 145 mg).

Under this alliance, Athena will establish and fund AtorFen™ manufacturing capabilities in India and through partnerships with regional and country level pharmaceutical companies develop and, once approved, commercialize the product. Veloxis will transfer its technology for manufacturing of AtorFen™ to Athena, with all expenses funded by Athena, and Veloxis will retain 70% of all revenues generated (subject to a minimum royalty rate). Veloxis will retain the right to re-claim major territories or regions where third party distributors are not established by Athena within certain time intervals.

"This alliance will enable Veloxis to establish a competitive presence for AtorFen™ in emerging markets," said William Polvino, M.D., chief executive officer of Veloxis. "Substantial future growth in the pharmaceutical industry is expected to come from this region where cardiovascular morbidity is on the rise. We're delighted to have the opportunity to work with Athena, a company that is well positioned in emerging markets. This agreement is part of our strategy to out-license our cardiovascular portfolio to partners who can realize the full value of these assets."

Financial guidance

The content of this release will have no influence on the company's financial guidance for 2011 which was provided on 1 March 2011 in connection with the release of the financial results for 2010.

For More Information Contact:

Veloxis Pharmaceuticals A/S

Johnny Stilou

William Polvino

CFO

President and CEO

Phone: (+45) 21 227 227

Phone: (+1) 732 321 3202

Email: jst@veloxis.com

Email: wjp@veloxis.com

 

About Veloxis Pharmaceuticals A/S

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

For further information, please visit www.veloxis.com.

 

 

 

SOURCE Veloxis Pharmaceuticals A/S

Contact:
Veloxis Pharmaceuticals A/S
Athena Drug Delivery Solutions Pvt. Ltd.
Web: http://www.veloxis.com




Review Article Be the first to review this article

EMA:

Featured Video
Editorial
Peggy AycinenaWhat Would Joe Do?
by Peggy Aycinena
Retail Therapy: Jump starting Black Friday
Peggy AycinenaIP Showcase
by Peggy Aycinena
REUSE 2016: Addressing the Four Freedoms
More Editorial  
Jobs
AE-APPS SUPPORT/TMM for EDA Careers at San Jose-SOCAL-AZ, CA
ACCOUNT MANAGER MUNICH GERMANY EU for EDA Careers at MUNICH, Germany
Development Engineer-WEB SKILLS +++ for EDA Careers at North Valley, CA
Principal Circuit Design Engineer for Rambus at Sunnyvale, CA
Manager, Field Applications Engineering for Real Intent at Sunnyvale, CA
FAE FIELD APPLICATIONS SAN DIEGO for EDA Careers at San Diego, CA
Upcoming Events
Zuken Innovation World 2017, April 24 - 26, 2017, Hilton Head Marriott Resort & Spa in Hilton Head Island, SC at Hilton Head Marriott Resort & Spa Hilton Head Island NC - Apr 24 - 26, 2017
CST Webinar Series



Internet Business Systems © 2016 Internet Business Systems, Inc.
595 Millich Dr., Suite 216, Campbell, CA 95008
+1 (408)-337-6870 — Contact Us, or visit our other sites:
AECCafe - Architectural Design and Engineering TechJobsCafe - Technical Jobs and Resumes GISCafe - Geographical Information Services  MCADCafe - Mechanical Design and Engineering ShareCG - Share Computer Graphic (CG) Animation, 3D Art and 3D Models
  Privacy Policy